Weekly profile.DIAGNOSTICS PRODUCT CORP. Symbol: DP Exchange: NYSE NYSE See: New York Stock Exchange Close: $51.00 1-WK % Chg: -2.0% Business Overview Diagnostic Products Corporation (DPC DPC Department of Premier and Cabinet (Victoria, Australia) DPC Dutch Power Cows DPC Deferred Procedure Calls (Microsoft Windows NT 4. ) develops, manufactures and markets immunodiagnostic immunodiagnostic pertaining to diagnosis by immune reactions. systems and immunochemistry Immunochemistry A discipline concerned both with the structure of antibody (immunoglobulin) molecules and with their ability to bind an apparently limitless number of diverse chemical structures (antigens); with the structure, organization, and rearrangement kits used throughout the world in hospital, reference and physicians' office laboratories, as well as in veterinary, forensic and research facilities. The test kits utilize technology derived from immunology and molecular biology to obtain precise, rapid identification and measurement of medically significant chemical substances that are often present at infinitesimal in·fin·i·tes·i·mal adj. 1. Immeasurably or incalculably minute. 2. Mathematics Capable of having values approaching zero as a limit. n. 1. concentrations. These include hormones, cytokines Cytokines Chemicals made by the cells that act on other cells to stimulate or inhibit their function. Cytokines that stimulate growth are called "growth factors. , vitamins, drugs, transport proteins, antibodies and biochemical markers of viruses and other microrganisms. The main clinical applications of DPC's immunoassays (test kits) relate to the diagnosis and management of thyroid, reproductive and cardiac disorders; allergies, infectious diseases, anemia, diabetes and certain types of cancer; bone metabolism disorders, and therapeutic drug administration. [GRAPHICS OMITTED] Income Statement LTM * 2004 Revenue (billions) $465.0 $443.2 Operating Income (million) 81.2 79.1 Net Income (million) 64.7 61.7 Eps $2.15 $2.06 Summary Headquarters: Los Angeles Market Cap: $1.56 billion Dividend Yield: 0.6% P/E Ratio: 23.7 * Latest twelve months ended June 2005 |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion